Secondly, different GCs had significantly different TIME, that is, GC2 and GC3 had higher immune infiltration and were more likely to respond to ICB treatment, suggesting that this classification approach may facilitate the development of personalized ICB treatment strategies for osteosarcoma. Here, SLC25A18 is linked to osteosarcoma.